PMID- 25131388
OWN - NLM
STAT- MEDLINE
DCOM- 20150827
LR  - 20180816
IS  - 1600-0447 (Electronic)
IS  - 0001-690X (Linking)
VI  - 131
IP  - 2
DP  - 2015 Feb
TI  - Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in 
      drug-naive patients with bipolar II disorder after a twelve-week pharmacological 
      intervention.
PG  - 120-8
LID - 10.1111/acps.12324 [doi]
AB  - OBJECTIVE: Brain-derived neurotrophic factor (BDNF) is thought to be involved in 
      the pathophysiology of bipolar disorder (BD) and metabolic syndrome. We 
      investigated the correlation between plasma BDNF with mood symptoms and metabolic 
      indices in patients with BD-II over a 12-week pharmacological intervention. 
      METHOD: Drug-naive patients with BD-II (n=117) were recruited. Metabolic profiles 
      [cholesterol, triglyceride, HbA1C, fasting serum glucose, body mass index (BMI)] 
      and plasma BDNF wtrun "tblautotrun "tblsctrun "tbl_contere measured at baseline 
      and 2, 8, and 12 weeks after beginning medication. To adjust within-subject 
      dependence over repeated assessments, multiple linear regressions with 
      generalized estimating equation methods were used. RESULTS: Seventy-six (65.0%) 
      patients completed the intervention. Plasma BDNF levels were significantly 
      associated with BMI (P=9.6E-5), low-density lipoprotein (P=0.034) and total 
      (P=0.001) cholesterol, but not with the Hamilton Depression Rating Scale-17 and 
      Young Mania Rating Scale scores over the 12-week treatment. CONCLUSION: We found 
      initial evidence of a positive correlation between plasma BDNF levels and BMI, 
      low-density lipoprotein and total cholesterol in drug-naive patients with BD-II. 
      The specific function of BDNF in regulating and maintaining peripheral metabolic 
      health requires additional investigation.
CI  - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Lee, S-Y
AU  - Lee SY
AD  - Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 
      Department of Psychiatry, College of Medicine, National Cheng Kung University, 
      Tainan, Taiwan.
FAU - Chen, S-L
AU  - Chen SL
FAU - Chang, Y-H
AU  - Chang YH
FAU - Chen, P-S
AU  - Chen PS
FAU - Huang, S-Y
AU  - Huang SY
FAU - Tzeng, N-S
AU  - Tzeng NS
FAU - Wang, C-L
AU  - Wang CL
FAU - Wang, L-J
AU  - Wang LJ
FAU - Lee, I-H
AU  - Lee IH
FAU - Wang, T-Y
AU  - Wang TY
FAU - Chen, K-C
AU  - Chen KC
FAU - Yang, Y-K
AU  - Yang YK
FAU - Hong, J-S
AU  - Hong JS
FAU - Lu, R-B
AU  - Lu RB
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140806
PL  - United States
TA  - Acta Psychiatr Scand
JT  - Acta psychiatrica Scandinavica
JID - 0370364
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Lipoproteins, LDL)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - O26FZP769L (Lorazepam)
SB  - IM
MH  - Adult
MH  - Affect/drug effects
MH  - Bipolar Disorder/*blood/*drug therapy/psychology
MH  - Body Mass Index
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cholesterol/blood
MH  - Female
MH  - Fluoxetine/therapeutic use
MH  - Humans
MH  - Linear Models
MH  - Lipoproteins, LDL/blood
MH  - Longitudinal Studies
MH  - Lorazepam/therapeutic use
MH  - Male
MH  - Metabolic Syndrome/blood/metabolism
MH  - Psychiatric Status Rating Scales
MH  - Treatment Outcome
MH  - Valproic Acid/therapeutic use
OTO - NOTNLM
OT  - bipolar II disorder
OT  - body mass index
OT  - brain-derived neurotrophic factor
OT  - metabolic syndrome
EDAT- 2014/08/19 06:00
MHDA- 2015/08/28 06:00
CRDT- 2014/08/19 06:00
PHST- 2014/07/08 00:00 [accepted]
PHST- 2014/08/19 06:00 [entrez]
PHST- 2014/08/19 06:00 [pubmed]
PHST- 2015/08/28 06:00 [medline]
AID - 10.1111/acps.12324 [doi]
PST - ppublish
SO  - Acta Psychiatr Scand. 2015 Feb;131(2):120-8. doi: 10.1111/acps.12324. Epub 2014 
      Aug 6.